ENLIE Pharmaceutical JSC (HSTC:BCP) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HSTC:BCP ENLIE Pharmaceutical JSC HSTC:BCP
25 GF Score
Price ₫10,600.00
View Full Analysis

What is ENLIE Pharmaceutical JSC 5-Year Yield-on-Cost %?

ENLIE Pharmaceutical JSC HSTC:BCP 25 5-Year Yield-on-Cost % is 0.00 as of Jul. 14, 2026. GuruFocus rates HSTC:BCP with a GF Score™ of 25/100. Among 516 Drug Manufacturers companies, ENLIE Pharmaceutical JSC ranks worse than 193798.26% on this metric.

ENLIE Pharmaceutical JSC's yield on cost for the quarter that ended in . 20 was 0.00.


The historical rank and industry rank for ENLIE Pharmaceutical JSC's 5-Year Yield-on-Cost % or its related term are showing as below:



HSTC:BCP's 5-Year Yield-on-Cost % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.205
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

ENLIE Pharmaceutical JSC  (HSTC:BCP) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.

ENLIE Pharmaceutical JSC 5-Year Yield-on-Cost % Related Terms

HSTC:BCP vs : 5-Year Yield-on-Cost % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, ENLIE Pharmaceutical JSC's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ENLIE Pharmaceutical JSC 5-Year Yield-on-Cost % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ENLIE Pharmaceutical JSC's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where ENLIE Pharmaceutical JSC's 5-Year Yield-on-Cost % falls into.


HSTC:BCP
25GF Score
ENLIE Pharmaceutical JSC HSTC:BCP
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ENLIE Pharmaceutical JSC 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of ENLIE Pharmaceutical JSC is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
ENLIE Pharmaceutical JSC (HSTC:BCP) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 14, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on ENLIE Pharmaceutical JSC and its competitors. According to the industry distribution chart, ENLIE Pharmaceutical JSC ranks #999999 out of 516 companies in the Drug Manufacturers industry.
Is ENLIE Pharmaceutical JSC's 5-Year Yield-on-Cost % too high?
ENLIE Pharmaceutical JSC's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, ENLIE Pharmaceutical JSC ranks #999999 out of 516 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, ENLIE Pharmaceutical JSC has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does ENLIE Pharmaceutical JSC's 5-Year Yield-on-Cost % compare to ?
According to the Drug Manufacturers industry distribution chart, ENLIE Pharmaceutical JSC ranks #999999 out of 516 companies for 5-Year Yield-on-Cost %. This places ENLIE Pharmaceutical JSC in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.21. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.21, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on ENLIE Pharmaceutical JSC and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ENLIE Pharmaceutical JSC's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ENLIE Pharmaceutical JSC stock overvalued right now?
ENLIE Pharmaceutical JSC (HSTC:BCP) has a current 5-Year Yield-on-Cost % of 0.00. The current 5-Year Yield-on-Cost % is 0.00. ENLIE Pharmaceutical JSC's overall GF Score™ is 25/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For ENLIE Pharmaceutical JSC (HSTC:BCP), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ENLIE Pharmaceutical JSC Business Description

Comparable Companies
Address NA6 Street, My Phuoc 2 Industrial Park, Ben Cat district, Binh Duong, VNM
ENLIE Pharmaceutical JSC is engaged in the production and trading of pharmaceuticals, medical supplies, cosmetics, foods, and functional foods. It is also engaged in the wholesale of other installation materials and equipment in the construction.
25GF Score

Get the complete analysis for HSTC:BCP

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₫10,600.00
Price